ThinPrep Pap Test Offers Improved Slide Preparation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System for cervical cancer screening has received FDA approval and is now available. The system offers an improved method of preparing Pap smears over the conventional method, leading to fewer retests due to compromised smears and potentially fewer missed abnormalities.

MARLBOROUGH, Mass--Cytyc Corporation's ThinPrep 2000 System forcervical cancer screening has received FDA approval and is nowavailable. The system offers an improved method of preparing Papsmears over the conventional method, leading to fewer retestsdue to compromised smears and potentially fewer missed abnormalities.

With the ThinPrep Pap test, the physician collects the cervicalcells in the traditional way, but rather than smearing a smallportion of the cells onto a slide, the physician rinses the cellsfrom the collection device into a vial filled with preservativesolution. This vial is then sent to the lab where the ThinPrep2000 Processor disperses and filters its contents to reduce mucus,blood, and inflammation, and applies a thin, even layer of cellsto a microscope slide.

Related Videos
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
The randomized, placebo-controlled, double-blind phase 3 CALLA trial assessed the combination of durvalumab and chemoradiotherapy vs placebo and chemoradiotherapy.
Findings from the phase 3 CALLA trial indicated that intensity modulated radiation therapy was administered in 88.1% of patients with high-risk locally advanced cervical cancer treated with durvalumab and chemoradiotherapy vs 88.1% with placebo and chemoradiotherapy.
Jyoti S. Mayadev, MD, indicated that durvalumab (Imfinzi) plus chemotherapy resulted in low rates of high-grade late-onset toxicities in the phase 3 CALLA trial, which may be due in part to the quality of the technology employed during the study.
Jyoti S. Mayadev, MD, indicated that future research for cervical cancer will be focused on combination immune checkpoint inhibitors and biomarker research.
Durvalumab appeared to have no impact on the ability to deliver safe and timely radiation therapy to patients with high-risk locally advanced cervical cancer, according to Jyoti S. Mayadev, MD.
The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.
Cervical Cancer
woman speaking with physician
Related Content